Archives of Cardiovascular Diseases最新文献

{"title":"Transfusion and coagulation management in acute type A aortic dissection.","authors":"Philipp Pfeiffer, Vanessa Buchholz, Chris Probst, Ahmed Ghazy, René Rissel, Jan Griesinger, Hendrik Treede, Daniel-Sebastian Dohle","doi":"10.1016/j.acvd.2025.02.004","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.02.004","url":null,"abstract":"<p><strong>Background: </strong>In acute type A dissection, the coagulation system is impaired by the dissection and its complications as well as the use of the heart-lung machine with hypothermia. Because of the critical importance of effective haemostasis at the end of the operation, the use of coagulation products and blood transfusions is usually unavoidable.</p><p><strong>Aim: </strong>This retrospective study aims to analyse the use of blood products and coagulation factors in the context of acute aortic dissections, and the factors influencing their use.</p><p><strong>Methods: </strong>Between 2017 and 2022, 369 patients were operated on for acute type A dissection. Clinical details, including the status at presentation and perioperatively administered transfusions and coagulation factors were obtained, and patients were stratified according to the Penn classification. A multivariable linear regression analysis for transfusions and coagulation factors was conducted, including typical risk factors.</p><p><strong>Results: </strong>The use of perioperatively required transfusions and coagulation factor (prothrombin complex concentrate and fibrinogen) substitution increased significantly with a higher ischaemic burden, including both localized and generalized malperfusion (Penn A<B<C<BC; P≤0.017). Multivariable linear regression analysis revealed that, besides generalized ischaemia, duration of cardiopulmonary bypass, extent of surgery and patient size were other significant factors.</p><p><strong>Conclusions: </strong>Surgical repair for acute type A dissection remains major surgery, requiring transfusions and coagulation factors in almost all patients. The ischaemic burden was identified as the most important factor that necessitates the use of these products, and was associated with early death. With proper management, acceptable rethoracotomy and chest drain rates with good clinical outcomes can be achieved.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flecainide falls short in preventing atrial arrhythmias after patent foramen ovale closure: Lessons from the AFLOAT trial.","authors":"Marie Hauguel-Moreau, Gilles Montalescot","doi":"10.1016/j.acvd.2025.02.006","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.02.006","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New 2024 European Society of Cardiology guidelines on peripheral arterial and aortic diseases: Will they change our clinical practice in France?","authors":"Victor Aboyans, Lucie Chastaingt, Romain Chauvet, Serge Kownator","doi":"10.1016/j.acvd.2025.02.005","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.02.005","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis of patients with acute myocardial infarction in the setting of COVID-19: A French nationwide observational study.","authors":"Ahmad Abou Hamed, Maeva Gourraud, Thibaud Genet, François Barbier, Denis Angoulvant, Laurent Fauchier, Fabrice Ivanes","doi":"10.1016/j.acvd.2025.01.008","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.01.008","url":null,"abstract":"<p><strong>Background: </strong>The prognosis of patients with acute myocardial infarction (AMI) in the setting of coronavirus disease 2019 (COVID-19) remains uncertain.</p><p><strong>Aims: </strong>To evaluate patients' prognosis after an AMI concomitant with COVID-19.</p><p><strong>Methods: </strong>This retrospective nationwide observational cohort study was based on the French administrative hospital discharge database. Primary outcomes were incidences of all-cause death, cardiovascular death, heart failure (HF), recurrence of AMI, ischaemic stroke, incident atrial fibrillation (AF), ventricular tachycardia/ventricular fibrillation (VT/VF) and cardiac arrest. Patients with AMI and COVID-19 were matched to those without COVID-19 (using propensity score matching techniques) to account for differences between the two populations.</p><p><strong>Results: </strong>A total of 288,408 patients hospitalized for AMI in France from March 2020 to January 2023 were included; 26,879 had a COVID-19-positive test between 15 days before to 5 days after admission. Patients with COVID-19 were older, more frequently had diabetes mellitus and obesity but less frequently smoked. They more frequently had non-ST-segment elevation myocardial infarction presentation and more often had lung disease. After matching, patients with COVID-19 had higher risks of all-cause death (hazard ratio [HR] 1.255; 95% confidence interval [CI] 1.203-1.308; P<0.0001), HF (HR 1.205; 95% CI 1.159-1.254; P<0.0001), ischaemic stroke (HR 1.237; 95% CI 1.084-1.411; P=0.002), incident AF (HR 1.160; 95% CI 1.070-1.258; P=0.0003) and VT/VF (1.360; 95% CI 1.200-1.540; P<0.0001). Surprisingly, cardiovascular death risk was lower in patients with COVID-19 (HR 0.932; 95% CI 0.879-0.988; P=0.02) as a result of competition with non-cardiovascular death. No statistical difference was found for cardiac arrest or recurrent AMI.</p><p><strong>Conclusion: </strong>In this French nationwide cohort study, AMI in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increased all-cause death incidence compared to non-infected AMI, but this poorer prognosis was not due to cardiovascular death. Further investigations are needed to elucidate the aetiologies of death.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Death on waiting list for transcatheter aortic valve implantation: Current incidence, clinical characteristics and predictive factors.","authors":"Hugo Poinsignon, Matthieu Godin, Quentin Landolff, Virginie Heroguelle, Aurélien Villecourt, Sophie Tassan-Mangina, Damien Metz, René Koning, Bruno Devaux, Alexandre Canville, Laurent Faroux","doi":"10.1016/j.acvd.2025.02.003","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.02.003","url":null,"abstract":"<p><strong>Background: </strong>The rapid and exponential growth in demand for transcatheter aortic valve implantation (TAVI) tends to overwhelm current capacity, leading to prolonged waiting times for TAVI.</p><p><strong>Aims: </strong>To investigate current waiting times for TAVI, the incidence of death on waiting list for TAVI, clinical characteristics and factors predictive of death before TAVI.</p><p><strong>Methods: </strong>A total of 1495 patients referred for TAVI in two French centres (TAVI centre, n=790; and non-TAVI centre, n=705) were included for analysis.</p><p><strong>Results: </strong>The mean age of the population was 82years. The median waiting time was 79 (interquartile range: 49-119) days, and was longer in the non-TAVI centre than in the TAVI centre (105 vs. 64days; P<0.001). The overall rate of death on waiting list was 5.8% (n=86), with the majority of deaths related to cardiovascular causes. Most patients (63%) died within the first 2months on the waiting list, with a linear occurrence of death without clear threshold. Impaired renal function (odds ratio: 2.12, 95% confidence interval: 1.30-3.45; P=0.003) and left ventricular ejection fraction<50% (odds ratio: 2.90, 95% confidence interval: 1.83-4.62; P<0.001) were identified as independent predictors of death on waiting list.</p><p><strong>Conclusions: </strong>The delay between patient referral and TAVI procedure is longer than 2.5months in half of cases, with a steady increase over the years and longer delays in centres without on-site TAVI facilities. One in 20 patients dies while on the waiting list for TAVI, with two thirds of deaths occurring within the first 2months on the waiting list. Impaired renal function and left ventricular ejection fraction<50% determine an increased risk of death.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients: The DAI-PP programme","authors":"Diana My Frodi ,&nbsp;Serge Boveda ,&nbsp;Victor Fournier ,&nbsp;Fawzi Kerkouri ,&nbsp;Frederic Anselme ,&nbsp;Jean-Claude Deharo ,&nbsp;Fabrice Extramiana ,&nbsp;Laurent Fauchier ,&nbsp;Estelle Gandjbakhch ,&nbsp;Daniel Gras ,&nbsp;Alexis Hermida ,&nbsp;Laurence Jesel-Morel ,&nbsp;Christophe Leclercq ,&nbsp;Nicolas Lellouche ,&nbsp;Aymeric Menet ,&nbsp;Kumar Narayanan ,&nbsp;Olivier Piot ,&nbsp;Vincent Probst ,&nbsp;Nicolas Sadoul ,&nbsp;Jerome Taieb ,&nbsp;Rodrigue Garcia","doi":"10.1016/j.acvd.2024.10.335","DOIUrl":"10.1016/j.acvd.2024.10.335","url":null,"abstract":"<div><h3>Background</h3><div>Patient characteristics, technology and clinical practice surrounding primary prevention implantable cardioverter defibrillators have evolved continuously over time.</div></div><div><h3>Aim</h3><div>To explore the temporal changes in patient characteristics, pharmacological therapy and device types among implantable cardioverter defibrillator recipients implanted for the primary prevention of sudden cardiac death over the last two decades in France.</div></div><div><h3>Methods</h3><div>Characteristics of participants and type of device from the retrospective DAI-PP Pilot Study (2002–2012) were compared with those from the ongoing prospective DAI-PP Consortium (2018 onwards).</div></div><div><h3>Results</h3><div>This study included 9588 participants overall (DAI-PP Pilot Study, <em>n</em> <!-->=<!--> <!-->5539; DAI-PP Consortium, <em>n</em> <!-->=<!--> <!-->4049). Compared with the DAI-PP Pilot Study, the DAI-PP Consortium subjects were older at implantation (62.5 vs 65.2 years; <em>P</em> <!-->=<!--> <!-->0.001) and had a higher proportion of women (15.1% vs 20.6%; <em>P</em> <!-->&lt;<!--> <!-->0.001), a similar proportion of ischaemic heart disease (60.2% vs 60.2%; <em>P</em> <!-->=<!--> <!-->0.98), a higher left ventricular ejection fraction (27<!--> <!-->±<!--> <!-->7% vs 30<!--> <!-->±<!--> <!-->8%; <em>P</em> <!-->&lt;<!--> <!-->0.001) and more patients with narrow QRS complexes (30.5% vs 46.0%; <em>P</em> <!-->&lt;<!--> <!-->0.001). The proportion of patients treated with heart failure drugs increased significantly (70.1% vs 83.1%; <em>P</em> <!-->&lt;<!--> <!-->0.001), whereas the use of amiodarone became much less frequent (22.7% vs 14.7%; <em>P</em> <!-->&lt;<!--> <!-->0.001). Finally, the proportions of cardiac resynchronization therapy defibrillators (53.8% vs 46.4%; <em>P</em> <!-->&lt;<!--> <!-->0.001) and dual-chamber defibrillators (23.3% vs 17.3%; <em>P</em> <!-->&lt;<!--> <!-->0.001) decreased, whereas subcutaneous implantable cardioverter defibrillators now account for a sizeable proportion of implants (14.6%).</div></div><div><h3>Conclusions</h3><div>Over a 20-year period, the primary prevention implantable cardioverter defibrillator population has evolved significantly, with an older age and a higher proportion of women. The type of device has changed, with fewer cardiac resynchronization therapy defibrillators and more subcutaneous implantable cardioverter defibrillators.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 3","pages":"Pages 178-184"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specific and non-specific prognostic scores in patients with out-of-hospital cardiac arrest caused by ST-segment elevation myocardial infarction: A comparative study","authors":"Vincent Pham ,&nbsp;Tahar Ghannam ,&nbsp;Olivier Varenne ,&nbsp;Alain Cariou ,&nbsp;Florence Dumas ,&nbsp;Donia Mafi ,&nbsp;Fabien Picard","doi":"10.1016/j.acvd.2024.12.011","DOIUrl":"10.1016/j.acvd.2024.12.011","url":null,"abstract":"<div><h3>Background</h3><div>Patients resuscitated after out-of-hospital cardiac arrest (OHCA) have a poor prognosis, with high death rates. Multiple scoring systems have been developed to predict survival in all-comers with OHCA. Acute coronary syndromes and ST-segment elevation myocardial infarction (STEMI) are the primary causes of OHCA. Recently, a specific prognostic score (Tran risk model) was developed for patients with STEMI-related OHCA.</div></div><div><h3>Aim</h3><div>To compare the accuracy of established non-STEMI-specific prognostic scores (OHCA, modified CAHP and NULL-PLEASE) with the Tran risk model in predicting in-hospital death among patients with STEMI-related OHCA.</div></div><div><h3>Methods</h3><div>This was an observational single-centre study including 315 consecutive patients treated for STEMI-related OHCA. The OHCA score was calculated for 310 patients (98.4%), the NULL-PLEASE and modified CAHP (mCAHP) scores were calculated for 308 patients (97.8%) and the Tran risk model score was calculated for 306 patients (97.1%). A C-statistic analysis was performed to determine score performance.</div></div><div><h3>Results</h3><div>The area under the curve (AUC) for the Tran risk model was 0.75 (95% confidence interval [CI] 0.69–0.79). The AUCs for the OHCA, mCAHP and NULL-PLEASE scores were 0.74 (95% CI 0.69–0.80), 0.74 (95% CI 0.69–0.80) and 0.76 (95% CI 0.71–0.82), respectively. There was no significant difference in AUCs between the Tran risk model and the mCAHP score (<em>P</em> <!-->=<!--> <!-->0.95), the NULL-PLEASE score (<em>P</em> <!-->=<!--> <!-->0.42) or the OHCA score (<em>P</em> <!-->=<!--> <!-->0.93). Similarly, no significant difference was observed between the mCAHP, NULL-PLEASE and OHCA scores. Predictors of death were no-flow duration, diabetes, blood lactate, femoral access and age<!--> <!-->&gt;<!--> <!-->75 years.</div></div><div><h3>Conclusions</h3><div>The OHCA, NULL-PLEASE and mCAHP scores and the Tran risk model showed moderate to good performance in predicting in-hospital death in patients with STEMI-related OHCA. No differences in accuracy were found between non-STEMI-specific scores and the Tran risk model developed for patients with STEMI-related OHCA.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 3","pages":"Pages 161-169"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term clinical outcomes in patients with acute myocardial infarction with multivessel disease and complete revascularization: Insights from the FLOWER-MI trial, the FRAME-AMI trial and the FAST-MI 2015 registry","authors":"Thibault Remy ,&nbsp;Nicolas Danchin ,&nbsp;Etienne Puymirat","doi":"10.1016/j.acvd.2024.10.329","DOIUrl":"10.1016/j.acvd.2024.10.329","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 3","pages":"Pages 199-201"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments","authors":"Simon Travers ,&nbsp;Joachim Alexandre ,&nbsp;Lauren A. Baldassarre ,&nbsp;Joe Elie Salem ,&nbsp;Mariana Mirabel","doi":"10.1016/j.acvd.2024.12.012","DOIUrl":"10.1016/j.acvd.2024.12.012","url":null,"abstract":"<div><div>Diagnosing cancer therapy-related cardiovascular toxicities may be a challenge. The interplay between cancer and cardiovascular diseases, beyond shared cardiovascular and cancer risk factors, and the increasingly convoluted cancer therapy schemes have complicated cardio-oncology. Biomarkers used in cardio-oncology include serum, imaging and rhythm modalities to ensure proper diagnosis and prognostic stratification of cardiovascular toxicities. For now, troponin and natriuretic peptides, multimodal cardiovascular imaging (led by transthoracic echocardiography combined with cardiac magnetic resonance or computed tomography angiography) and electrocardiography (12-lead or Holter monitor) are cornerstones in cardio-oncology. However, the imputability of cancer therapies is sometimes difficult to assess, and more refined biomarkers are currently being studied to increase diagnostic accuracy. Advances reside partly in pathophysiology-based serum biomarkers, improved cardiovascular imaging through new technical developments and remote monitoring for rhythm disorders. A multiparametric omics approach, enhanced by deep-learning techniques, should open a new era for biomarkers in cardio-oncology in the years to come.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 3","pages":"Pages 185-198"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of simulation-based training in transoesophageal echocardiography: Insights from the SIMULATOR randomized clinical trial","authors":"Théo Pezel ,&nbsp;Clémence Thébaut ,&nbsp;Yohann Bohbot ,&nbsp;Charles Fauvel ,&nbsp;Basile Mouhat ,&nbsp;Yoan Lavie Badie ,&nbsp;Lee S. Nguyen ,&nbsp;Loïc Bière ,&nbsp;Florent Le Ven ,&nbsp;Sophie Ribeyrolles ,&nbsp;Julien Dreyfus ,&nbsp;Jennifer Cautela ,&nbsp;Théo Cambet ,&nbsp;Thierry Le Tourneau ,&nbsp;Erwan Donal ,&nbsp;Nicolas Mansencal ,&nbsp;Julien Magne ,&nbsp;Anne Bernard ,&nbsp;Augustin Coisne ,&nbsp;on behalf of the SIMULATOR investigators","doi":"10.1016/j.acvd.2024.10.330","DOIUrl":"10.1016/j.acvd.2024.10.330","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 3","pages":"Pages 202-204"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}